The Food and Drug Administration draft guidance published on 19 December explains how the agency determines if real-world data (RWD) is sufficient for generating real-world evidence (RWE) that can be used when making regulatory decisions on medical devices.
The document, “Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices,” expands recommendations to the 2017 guidance,...
Welcome to Medtech Insight
Create an account to read this article
Already a subscriber?